SMARCA4 and neuroendocrine carcinoma: The study of SMARCA4 deletion in a large number of lung cancer samples using second-generation sequencing technology revealed the presence of SMARCA4 deletion in neuroendocrine carcinomas, as previously reported by Gandhi et al (4).